Terns Narrows Q2 Loss Amid R&D Cuts, Cash Runway to H2 2026
Ticker: TERN · Form: 10-Q · Filed: Aug 5, 2025 · CIK: 1831363
Sentiment: mixed
Topics: Biotechnology, Clinical Stage, Drug Development, Net Loss, R&D Expenses, Cash Runway, Metabolic Diseases
Related Tickers: TERN
TL;DR
**TERN is burning cash but extending its runway, making it a speculative bet on pipeline success, not a buy for the faint of heart.**
AI Summary
Terns Pharmaceuticals, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its clinical-stage status. The company's net loss for the three months ended June 30, 2025, was $35.2 million, a decrease from $40.1 million for the same period in 2024. For the six months ended June 30, 2025, the net loss was $70.5 million, compared to $78.9 million in 2024. Research and development expenses decreased to $28.1 million for the three months ended June 30, 2025, from $33.5 million in 2024, primarily due to reduced clinical trial activities for TERN-601 and TERN-501. General and administrative expenses remained relatively stable at $7.1 million for the three months ended June 30, 2025, versus $6.6 million in 2024. The company held $200.0 million in cash, cash equivalents, and marketable securities as of June 30, 2025, down from $235.0 million at December 31, 2024. This cash position is expected to fund operations into the second half of 2026. Key risks include the inherent uncertainties of drug development and the need for additional financing.
Why It Matters
For investors, Terns' reduced net loss and extended cash runway into the second half of 2026 provide a longer window for its pipeline to mature, particularly TERN-601 and TERN-501. However, the lack of revenue underscores the high-risk, high-reward nature of clinical-stage biotechs, where success hinges on trial outcomes. Employees face continued pressure to deliver on clinical milestones, as the company's future depends on successful drug development. Customers, specifically future patients, are directly impacted by the progress and eventual approval of Terns' therapeutic candidates for metabolic diseases. In a competitive landscape, Terns must demonstrate superior efficacy and safety to differentiate its drug candidates from those of larger pharmaceutical companies with deeper pockets.
Risk Assessment
Risk Level: high — The risk level is high because Terns Pharmaceuticals is a clinical-stage company with no revenue, reporting net losses of $35.2 million for Q2 2025 and $70.5 million for H1 2025. Its future depends entirely on the successful development and commercialization of drug candidates like TERN-601 and TERN-501, which face significant clinical and regulatory hurdles. The company's cash, cash equivalents, and marketable securities decreased from $235.0 million at December 31, 2024, to $200.0 million at June 30, 2025, indicating ongoing cash burn.
Analyst Insight
Investors should monitor TERN's upcoming clinical trial data for TERN-601 and TERN-501 closely, as these will be the primary catalysts for stock movement. Given the high-risk profile and lack of revenue, consider TERN a speculative investment suitable only for those with a high-risk tolerance and a long-term horizon, prepared for potential significant volatility.
Financial Highlights
- debt To Equity
- N/A
- revenue
- $0
- operating Margin
- N/A
- total Assets
- N/A
- total Debt
- N/A
- net Income
- -$35.2 million
- eps
- N/A
- gross Margin
- N/A
- cash Position
- $200.0 million
- revenue Growth
- N/A
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Total Revenue | $0 | N/A |
Key Numbers
- $0 — Revenue (for the three and six months ended June 30, 2025, indicating clinical-stage status)
- $35.2 million — Net Loss (for the three months ended June 30, 2025, a decrease from $40.1 million in 2024)
- $70.5 million — Net Loss (for the six months ended June 30, 2025, compared to $78.9 million in 2024)
- $28.1 million — Research and Development Expenses (for the three months ended June 30, 2025, down from $33.5 million in 2024)
- $200.0 million — Cash, Cash Equivalents, and Marketable Securities (as of June 30, 2025, expected to fund operations into H2 2026)
- $235.0 million — Cash, Cash Equivalents, and Marketable Securities (as of December 31, 2024, showing a decrease in cash reserves)
Key Players & Entities
- Terns Pharmaceuticals, Inc. (company) — filer of the 10-Q
- TERN-601 (drug_candidate) — key clinical-stage asset
- TERN-501 (drug_candidate) — key clinical-stage asset
- Hansoh Option and License Agreement (agreement) — licensing agreement mentioned in the filing
- Erin Quirk (person) — individual mentioned in the filing, likely an executive or board member
- Mr. Yoon and Dr. Vignola (person) — individuals mentioned in the filing, likely executives or board members
- SEC (regulator) — regulator of the 10-Q filing
FAQ
What were Terns Pharmaceuticals' revenues for Q2 2025?
Terns Pharmaceuticals, Inc. reported no revenue for the three and six months ended June 30, 2025, as it remains a clinical-stage biopharmaceutical company focused on drug development.
How did Terns Pharmaceuticals' net loss change in Q2 2025 compared to last year?
Terns Pharmaceuticals' net loss for the three months ended June 30, 2025, was $35.2 million, a decrease from $40.1 million for the same period in 2024.
What is Terns Pharmaceuticals' cash position and runway as of June 30, 2025?
As of June 30, 2025, Terns Pharmaceuticals held $200.0 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into the second half of 2026.
Why did Terns Pharmaceuticals' research and development expenses decrease in Q2 2025?
Research and development expenses decreased to $28.1 million for the three months ended June 30, 2025, from $33.5 million in 2024, primarily due to reduced clinical trial activities for TERN-601 and TERN-501.
What are the main risks for investors in Terns Pharmaceuticals?
The main risks for investors include the inherent uncertainties of drug development, the lack of current revenue, and the need for additional financing if clinical trials for candidates like TERN-601 and TERN-501 are prolonged or unsuccessful.
What are Terns Pharmaceuticals' key drug candidates?
Terns Pharmaceuticals' key drug candidates mentioned in the filing include TERN-601 and TERN-501, which are currently undergoing clinical trial activities.
How does Terns Pharmaceuticals plan to fund its operations?
Terns Pharmaceuticals plans to fund its operations using its existing cash, cash equivalents, and marketable securities, which totaled $200.0 million as of June 30, 2025, providing a runway into the second half of 2026.
What impact do reduced R&D expenses have on Terns Pharmaceuticals' future?
Reduced R&D expenses, while contributing to a narrower net loss, could potentially slow the progress of Terns Pharmaceuticals' drug candidates like TERN-601 and TERN-501, impacting their time to market and future revenue potential.
What is the significance of the 'Hansoh Option and License Agreement' for Terns Pharmaceuticals?
The 'Hansoh Option and License Agreement' is a significant partnership for Terns Pharmaceuticals, indicating a strategic collaboration that could provide future milestones or royalties, though specific financial impacts were not detailed in the Q2 2025 summary.
Should investors be concerned about Terns Pharmaceuticals' declining cash balance?
While Terns Pharmaceuticals' cash, cash equivalents, and marketable securities decreased from $235.0 million to $200.0 million, the company still projects a cash runway into the second half of 2026, which provides some stability, but continued monitoring of cash burn is essential.
Risk Factors
- Drug Development Uncertainty [high — operational]: Terns Pharmaceuticals is a clinical-stage biopharmaceutical company with no approved products. The success of its drug candidates, including TERN-601 and TERN-501, is subject to significant risks inherent in drug development, including clinical trial outcomes, regulatory approvals, and market acceptance. The company has incurred substantial net losses and may never achieve profitability.
- Need for Additional Financing [high — financial]: As of June 30, 2025, Terns Pharmaceuticals had $200.0 million in cash, cash equivalents, and marketable securities. This is projected to fund operations into the second half of 2026. However, the company will likely require substantial additional capital to fund its ongoing research and development activities, clinical trials, and potential commercialization efforts.
- Regulatory Approval Risks [high — regulatory]: The development and commercialization of pharmaceutical products are subject to stringent regulatory review by agencies such as the FDA. There is no guarantee that Terns Pharmaceuticals' drug candidates will receive the necessary approvals to be marketed. Delays or failures in the regulatory process can significantly impact the company's timeline and financial viability.
- Competition in Therapeutic Areas [medium — market]: The pharmaceutical industry is highly competitive. Terns Pharmaceuticals faces competition from other companies developing treatments for similar diseases. The success of its products will depend on their ability to demonstrate superior efficacy, safety, or convenience compared to existing or emerging therapies.
- Dependence on Key Personnel [medium — operational]: The company's success depends on its ability to attract and retain highly qualified scientific, clinical, and management personnel. The loss of key individuals could disrupt research and development efforts and strategic initiatives.
Industry Context
Terns Pharmaceuticals operates in the highly competitive biopharmaceutical sector, focusing on developing novel treatments for metabolic diseases. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Success hinges on innovation, clinical trial efficacy, and securing substantial funding for pipeline advancement.
Regulatory Implications
As a clinical-stage company, Terns Pharmaceuticals is subject to rigorous oversight from regulatory bodies like the FDA. The success of its drug candidates hinges on navigating complex clinical trial protocols and demonstrating safety and efficacy to gain market approval. Any delays or setbacks in the regulatory process pose a significant risk to the company's future.
What Investors Should Do
- Monitor R&D progress and clinical trial updates
- Assess cash burn rate and future financing needs
- Evaluate competitive landscape and market potential
Key Dates
- 2025-06-30: End of Second Quarter 2025 — Reported $200.0 million in cash, cash equivalents, and marketable securities, with an estimated runway into H2 2026. Net loss for the quarter was $35.2 million.
- 2024-12-31: End of Fiscal Year 2024 — Reported $235.0 million in cash, cash equivalents, and marketable securities, indicating a decrease in cash reserves by the end of Q2 2025.
- 2024-06-30: End of Second Quarter 2024 — Reported a net loss of $40.1 million for the three months ended June 30, 2024, and $33.5 million in R&D expenses.
Glossary
- Clinical-stage
- A company that is in the process of testing drug candidates in human clinical trials but has not yet received regulatory approval to market any products. (Explains why Terns Pharmaceuticals has no revenue and is incurring significant R&D expenses.)
- Net Loss
- The total expenses of a company exceed its total revenues over a specific period, resulting in a negative profit. (Indicates the company's current financial performance, showing a loss of $35.2 million for Q2 2025.)
- Research and Development Expenses
- Costs incurred by a company to discover, develop, and test new products or processes. (Represents a significant portion of Terns' operating expenses, reflecting investment in drug pipeline development.)
- Cash, Cash Equivalents, and Marketable Securities
- Highly liquid assets that can be readily converted into cash, representing a company's readily available funds. (Key indicator of the company's financial health and its ability to fund operations and future development.)
Year-Over-Year Comparison
Compared to the prior year period, Terns Pharmaceuticals has seen a reduction in its net loss for the three months ended June 30, 2025 ($35.2 million vs. $40.1 million in 2024) and for the six months ended June 30, 2025 ($70.5 million vs. $78.9 million in 2024). This improvement is largely attributed to a decrease in research and development expenses, specifically $28.1 million for Q2 2025 compared to $33.5 million in Q2 2024, driven by reduced clinical trial activities. While cash reserves have decreased from $235.0 million at the end of 2024 to $200.0 million as of June 30, 2025, the company maintains a sufficient cash position to fund operations into the second half of 2026. No new significant risks were highlighted, but the inherent uncertainties of drug development and the need for future financing remain prominent.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on August 5, 2025 by Erin Quirk regarding Terns Pharmaceuticals, Inc. (TERN).